Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

[EX Q]: Paragraph: Pfizer shares were up nearly 4 percent on positive findings for the oral treatment, called palbociclib, one of the company's most important experimental drugs that some analysts believe could eventually claim annual sales of more than $5 billion, if approved. The trial tested the pill in post-menopausal patients with locally advanced or newly diagnosed breast cancer that had spread to other parts of the body. "We are delighted with the final data," Pfizer said in a release, adding the company will discuss the successful data on progression-free survival with the U.S. Food and Drug Administration "to determine next steps" for palbociclib. A secondary goal of the study is to determine whether palbociclib can prolong overall survival. But Pfizer spokeswoman Sally Beatty said the company does not yet have such data, because it takes longer periods to follow patients and gauge survival trends. Although Pfizer is conducting two larger late-stage trials of palbociclib, ISI Group analyst Mark Schoenebaum noted the company has previously said it might discuss with the FDA the potential to seek approval of the medicine based upon mid-stage trial data, if the data warranted. Palbociclib, which blocks enzymes known as cyclin-dependent kinases (CDKs) 4 and 6, was taken in combination with a standard treatment called letrozole among women who were estrogen receptor positive - meaning tumors grow in response to estrogen - and HER2-negative, meaning that the HER2 protein is not causing the cancer. Such patients make up about 60 percent of advanced breast cancer cases. Letrozole is the chemical name of Femara, a Novartis AG drug that belongs to a class of treatments called aromatase inhibitors that block production of estrogen. Pfizer on Monday did not present detailed data from the trial results, saying they would be presented at a scientific meeting in San Diego in April. The success of the trial, called Paloma-1, follows highly favorable interim data that Pfizer unveiled in December 2012. At that point in the study, those taking both palbociclib and letrozole went an average of 26.1 months before tumors worsened. That compared with 7.5 months for those taking letrozole, but not palbociclib. The 18.6-month difference was considered statistically significant. Side effects from palbociclib were similar to those previously reported, Pfizer said on Monday. The earlier interim results had shown that patients taking the drug combination experienced anemia, fatigue and neutropenia - a decline in white blood cells called neutrophils that can put patients at higher risk of infection. Palbociclib was designated a "breakthrough" drug by the FDA last April based on initial data from the trial. The FDA grants "breakthrough" status to drugs that may offer substantial improvement over existing treatments for serious or life-threatening diseases. The status helps to speed up the approval process. Pfizer has started two late-stage trials of the drug - Paloma-2 and Paloma-3 - in patients with advanced breast cancer. Paloma-2 will test the same drug combination, palbociclib and letrozole, as an initial treatment for breast cancer. Paloma-3 will evaluate palbociclib in combination with another hormone therapy, fulvestrant, in women whose cancer has progressed after hormonal therapy. The drug, sold under the brand name Faslodex by AstraZeneca Plc, is called an estrogen receptor antagonist. Companies trying to develop treatments similar to palbociclib include Novartis and Eli Lilly & Co. Breast cancer killed more than 508,000 women worldwide in 2011, according to the World Health Organization. Pfizer shares were up 3.7 percent at $31.53 on Monday morning on the New York Stock Exchange. Claim: Pfizer breast cancer drug succeeds in mid-stage trial.
[EX A]: Pfizer Inc's experimental breast cancer drug significantly delayed progression of symptoms in a mid-stage trial, meeting the study's primary goal and keeping Pfizer in the forefront of a race for a new standard of care for the disease.

[EX Q]: Paragraph: Health and Human Services Secretary Alex Azar and Surgeon General Jerome Adams made the announcement, with Azar calling marijuana "a dangerous drug." Officials said President Donald Trump has donated $100,000 one-quarter of his annual government salary toward a digital campaign to raise awareness of the risks. Trump has forgone his official salary since taking office. The warning comes as legal marijuana has grown into a $10-billion industry in the U.S. with nearly two-thirds of states legalizing it, mainly for medical uses. Possessing small amounts of marijuana for adult recreational use is legal in 11 states and the District of Columbia, according to the National Conference of State Legislatures. The list includes California, Colorado, Michigan and Maine. Federal law still treats it as a controlled substance akin to opioids. Adams said science shows that marijuana is harmful to the developing brains of teenagers and to the human fetus. The drug has also gotten stronger, with a three-fold increase in the concentration of the active ingredient THC in cultivated plants over the last 20 years. "This ain't your mother's marijuana," Adams said. The American Medical Association said it strongly supports the government's effort, adding that it for some time it has been recommending against marijuana use by teens, pregnant women and women who are breastfeeding. The surgeon general said his advisory is a direct result of scientific research that runs counter to changing social mores. "Marijuana use is a risk to the developing brain," Adams said. "Over time there has been a change in attitudes about marijuana creating a false sense of security." While the White House has made the opioid epidemic a top policy and political priority, marijuana previously had not gotten such high-level attention. Federal officials say they fear the trend toward legalization may make it more enticing for teenagers to try marijuana. It's a commonly used drug among youths, they said, along with alcohol and e-cigarettes. No states allow recreational marijuana use by teens. States with medical marijuana programs, Illinois among them, generally allow use by minors with consent from a legal guardian and certification from a doctor. Adams said that for teens it carries a risk of affecting brain development, which continues in the 20s. Frequent marijuana use by teenagers is associated with changes in parts of the brain that are involved with attention, memory, decision-making and motivation. Among pregnant women, marijuana is the most commonly used illicit drug, with about 7% reporting they had used it within the past month in a 2017 study. Some women use it to help with morning sickness. The American College of Obstetricians and Gynecologists and the American Academy of Pediatrics advise women not to use marijuana during pregnancy, and to discontinue the drug if they find out they are pregnant. HHS Assistant Secretary for Health Brett Giroir said pregnant women taking marijuana to relieve morning sickness should stop. "If you have morning sickness, talk to your physician," said Giroir. "There are FDA-approved drugs to help with morning sickness. Taking marijuana for morning sickness has never been shown to be safe and effective." The government's National Institute on Drug Abuse is paying for several studies on marijuana use in pregnancy, including one involving women who have chosen to continue using the drug to treat morning sickness despite warnings. While some studies have suggested that marijuana may be harmful to the developing brain, the evidence isn't conclusive, explained NIDA Director Nora Volkow, who said she strongly supports the surgeon general's warning. "We cannot close our eyes and say this is not happening. It's happening," said Volkow. It would be a missed opportunity not to continue the research to find conclusive evidence on how the drug affects the fetus, she said. "My view is that the way that you change things is by providing evidence," she added. ___ Associated Press Medical Writer Lindsey Tanner in Chicago contributed to this article. Claim: 'This ain't your mother's marijuana,' surgeon general says.
[EX A]: Federal health officials issued a national warning Thursday against marijuana use by adolescents and pregnant women, as more states legalize the increasingly potent drug for medicinal and recreational use.

[EX Q]: Paragraph: "It would not be necessary for the story to discuss the costs of hormone therapy. The story adequately quantifies the increased risk in breast cancer. While the story does provide quantification in relative terms only for the WHI study (it mentions a 60% increase), it does use absolute numbers to quantify the increase in the American Cancer Society analysis (the story describes how the risk of breast cancer would increase from 1 in 52 to 1 in 26). The story mentions risk of stroke, heart disease and blood clots in addition to breast cancer. The story does a good job of describing the design of the current studies and pointing out that these ""observational"" retrospective survey studies are less reliable than more robust study designs. The story does not exaggerate the seriousness or prevalence of breast cancer. Everyone quoted was either involved in the study or works for the drug manufacturer. This is the main flaw in an otherwise high quality story. Because the point of the story is to discuss the risk of breast cancer associated with hormone therapy, it would not be necessary for the story to mention alternative treatment options. Clearly hormone therapy is available. Clearly hormone therapy is not a new idea. It's clear there was enterprise reporting involved in this story." Claim: Hormone use: Studies suggest two years max
[EX A]:
Hormone therapy remains the most effective treatment for menopausal symptoms (hot flashes, night sweats and vaginal dryness). However, it is clear that taking hormone therapy has certain risks stroke, heart attack, blood clots and if taken for five years breast cancer. New studies and analyses indicate that the breast cancer risk associated with hormone therapy goes up after 3 years and now women are being advised to stop taking the medication after 2 years if they wish to avoid this risk. Whether 2 years or 3 years should be the right cut-off for stopping hormone therapy remains controversial. What is not controversial is that women can safely take hormone therapy for short periods of time if they are bothered by menopausal symptoms, or chose among several other non-hormone therapy options. This story does a good job of describing the design of the latest studies and pointing out that these "observational" retrospective survey studies are less reliable than more robust study designs. The story adequately quantifies the increased risk of breast cancer. While the story does provide quantification in relative terms only for the WHI study (it mentions a 60% increase), it does use absolute numbers to quantify the increase in the American Cancer Society analysis (the story describes how the risk of breast cancer would increase from 1 in 52 to 1 in 26). Everyone quoted was either involved in the study or works for the drug manufacturer. This is the main flaw in an otherwise high quality story.